MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Capricor Therapeutics Inc

Затворен

9.73 2.75

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.11

Максимум

9.88

Ключови измерители

By Trading Economics

Приходи

5.4M

-7.1M

Продажби

8.9M

11M

EPS

-0.16

Марж на печалбата

-63.938

Служители

160

EBITDA

5.3M

-7.3M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+359.92% upside

Дивиденти

By Dow Jones

Следващи печалби

12.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-60M

526M

Предишно отваряне

6.98

Предишно затваряне

9.73

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Capricor Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.03.2025 г., 15:41 ч. UTC

Значими двигатели на пазара

Capricor Therapeutics Shares Rise on FDA Priority Review

Сравнение с други в отрасъла

Ценова промяна

Capricor Therapeutics Inc Прогноза

Ценова цел

By TipRanks

359.92% нагоре

12-месечна прогноза

Среден 43.6 USD  359.92%

Висок 77 USD

Нисък 25 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Capricor Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

5

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

9.0101 / 11.81Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.